

Dr. Christopher Fox leads the development of vaccine adjuvant formulations for clinical testing against a variety of infectious diseases. Since joining AAHI in 2007, he has served as Principal Investigator on multiple vaccine development grants and contracts involving pragmatic solutions to ensure equitably accessible products, including temperature-stable compositions, intranasally administered formulations, manufacturing process scale-up, and sustainable raw material sourcing. Moreover, Dr. Fox directs efforts to transfer adjuvant formulation manufacturing know-how and processes around the world to build local capacity. He has guided multiple adjuvant formulations from the lab bench to cGMP manufacturing, clinical testing, and technology transfer, resulting in over 130 publications. Dr. Fox obtained his PhD in Bioengineering at the University of Utah.